Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...